William Feehery
Chief Executive Officer bij CERTARA, INC.
Vermogen: 52 M $ op 31-03-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
James Cashman | M | 70 |
Certara Holdings, Inc.
Certara Holdings, Inc. Packaged SoftwareTechnology Services Part of Certara, Inc., Certara Holdings, Inc. develops software for clinical pharmacology. The private company is based in Princeton, NJ. William F. Feehery has been the CEO of the company since 2019.
Certara USA, Inc.
Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ. | 6 jaar |
Richard Traynor | M | 53 |
LA-SER Europe Ltd.
LA-SER Europe Ltd. Pharmaceuticals: MajorHealth Technology LA-SER is a strongly science driven late-phase company with offices in 7 countries (UK, France, Germany, Spain, Italy, Canada and Morocco) encompassing a team of 150 specialists in late-phase clinical research. They cover a full range of late-phase services from observational studies, cohorts, registries, case-control studies, surveys, electronic health care database studies, pragmatic trials, they excel in risk/benefit management, effectiveness/relative effectiveness studies, and strategic consulting for drug value assessment. A truly unique feature is their in-depth understanding & knowledge of the process of drug value assessment, and of the methods, paradigms & modus operandi of regulatory decision-making bodies & agencies in several countries. Originally brought to the company by the founders of the company, this in-depth network knowledge is now shared by a large number of their senior staff. They can therefore provide remarkable insight into what evidence is required to grant market authorisation & reimbursement, for new drugs across different European countries & North America.
Certara USA, Inc.
Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ. | 6 jaar |
Stephen McLean | M | 66 |
Certara Holdings, Inc.
Certara Holdings, Inc. Packaged SoftwareTechnology Services Part of Certara, Inc., Certara Holdings, Inc. develops software for clinical pharmacology. The private company is based in Princeton, NJ. William F. Feehery has been the CEO of the company since 2019.
Certara USA, Inc.
Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ. | 11 jaar |
Michael Schemick | M | 50 |
LA-SER Europe Ltd.
LA-SER Europe Ltd. Pharmaceuticals: MajorHealth Technology LA-SER is a strongly science driven late-phase company with offices in 7 countries (UK, France, Germany, Spain, Italy, Canada and Morocco) encompassing a team of 150 specialists in late-phase clinical research. They cover a full range of late-phase services from observational studies, cohorts, registries, case-control studies, surveys, electronic health care database studies, pragmatic trials, they excel in risk/benefit management, effectiveness/relative effectiveness studies, and strategic consulting for drug value assessment. A truly unique feature is their in-depth understanding & knowledge of the process of drug value assessment, and of the methods, paradigms & modus operandi of regulatory decision-making bodies & agencies in several countries. Originally brought to the company by the founders of the company, this in-depth network knowledge is now shared by a large number of their senior staff. They can therefore provide remarkable insight into what evidence is required to grant market authorisation & reimbursement, for new drugs across different European countries & North America.
Certara USA, Inc.
Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ. | 10 jaar |
Mason Slaine | M | 71 |
Certara Holdings, Inc.
Certara Holdings, Inc. Packaged SoftwareTechnology Services Part of Certara, Inc., Certara Holdings, Inc. develops software for clinical pharmacology. The private company is based in Princeton, NJ. William F. Feehery has been the CEO of the company since 2019.
Certara USA, Inc.
Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ. | 6 jaar |
Matthew Walsh | M | 57 |
Certara USA, Inc.
Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ.
Certara Holdings, Inc.
Certara Holdings, Inc. Packaged SoftwareTechnology Services Part of Certara, Inc., Certara Holdings, Inc. develops software for clinical pharmacology. The private company is based in Princeton, NJ. William F. Feehery has been the CEO of the company since 2019. | 7 jaar |
Eric Green | M | 55 | 9 jaar | |
Bernard Birkett | M | 55 | 6 jaar | |
Carol Gallagher | M | 59 |
Certara Holdings, Inc.
Certara Holdings, Inc. Packaged SoftwareTechnology Services Part of Certara, Inc., Certara Holdings, Inc. develops software for clinical pharmacology. The private company is based in Princeton, NJ. William F. Feehery has been the CEO of the company since 2019. | 2 jaar |
Sherilyn McCoy | F | 65 |
Certara Holdings, Inc.
Certara Holdings, Inc. Packaged SoftwareTechnology Services Part of Certara, Inc., Certara Holdings, Inc. develops software for clinical pharmacology. The private company is based in Princeton, NJ. William F. Feehery has been the CEO of the company since 2019. | 4 jaar |
Ethan Waxman | M | 35 |
Certara USA, Inc.
Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ. | 4 jaar |
Amin Rostami-Hodjegan | M | - |
Certara USA, Inc.
Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ. | - |
Rosemary Crane | F | 64 | 2 jaar | |
Stephen Lockhart | M | 65 | 2 jaar | |
Nancy Killefer | F | 69 | 3 jaar | |
Molly Joseph | F | 50 | 3 jaar | |
Silji Abraham | M | 52 | 6 jaar | |
David Spaight | M | 65 | 2 jaar | |
Deborah Keller | F | 61 | 7 jaar | |
Ellen Leinfuss | F | - |
Certara USA, Inc.
Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ. | - |
Leif Pedersen | M | 60 | 4 jaar | |
Mark Buthman | M | 63 | 13 jaar | |
Kimberly MacKay | F | 58 | 4 jaar | |
Myla Lai-Goldman | M | 66 | 10 jaar | |
Thomas Hofmann | M | 72 | 17 jaar | |
Eran Broshy | M | 65 | 2 jaar | |
Cindy Reiss-Clark | F | 50 | - | |
Robert Friel | M | 68 | 4 jaar | |
Paolo Pucci | M | 63 | 8 jaar | |
Cynthia Collins | F | 65 | 3 jaar | |
Douglas Michels | M | 66 | 13 jaar | |
Nicolette Sherman | F | - | 3 jaar | |
Thomas Kerbusch | M | 52 |
LA-SER Europe Ltd.
LA-SER Europe Ltd. Pharmaceuticals: MajorHealth Technology LA-SER is a strongly science driven late-phase company with offices in 7 countries (UK, France, Germany, Spain, Italy, Canada and Morocco) encompassing a team of 150 specialists in late-phase clinical research. They cover a full range of late-phase services from observational studies, cohorts, registries, case-control studies, surveys, electronic health care database studies, pragmatic trials, they excel in risk/benefit management, effectiveness/relative effectiveness studies, and strategic consulting for drug value assessment. A truly unique feature is their in-depth understanding & knowledge of the process of drug value assessment, and of the methods, paradigms & modus operandi of regulatory decision-making bodies & agencies in several countries. Originally brought to the company by the founders of the company, this in-depth network knowledge is now shared by a large number of their senior staff. They can therefore provide remarkable insight into what evidence is required to grant market authorisation & reimbursement, for new drugs across different European countries & North America. | - |
Robert Aspbury | M | 53 | 4 jaar | |
Josh Xie | M | - | 3 jaar | |
Richard James Wilson | M | 53 |
LA-SER Europe Ltd.
LA-SER Europe Ltd. Pharmaceuticals: MajorHealth Technology LA-SER is a strongly science driven late-phase company with offices in 7 countries (UK, France, Germany, Spain, Italy, Canada and Morocco) encompassing a team of 150 specialists in late-phase clinical research. They cover a full range of late-phase services from observational studies, cohorts, registries, case-control studies, surveys, electronic health care database studies, pragmatic trials, they excel in risk/benefit management, effectiveness/relative effectiveness studies, and strategic consulting for drug value assessment. A truly unique feature is their in-depth understanding & knowledge of the process of drug value assessment, and of the methods, paradigms & modus operandi of regulatory decision-making bodies & agencies in several countries. Originally brought to the company by the founders of the company, this in-depth network knowledge is now shared by a large number of their senior staff. They can therefore provide remarkable insight into what evidence is required to grant market authorisation & reimbursement, for new drugs across different European countries & North America. | - |
Warren Kanders | M | 66 |
Winston Churchill Foundation
| - |
Chad Winters | M | 45 | 5 jaar | |
Annette Favorite | F | 59 | 9 jaar | |
John Gallagher | M | 51 | 1 jaar | |
Herbert Winokur | M | 80 |
Winston Churchill Foundation
| - |
Nitin Patel | M | - |
Massachusetts Institute of Technology
| 29 jaar |
Ram Sasisekharan | M | 58 |
Massachusetts Institute of Technology
| 28 jaar |
Quintin Lai | M | 57 | 8 jaar | |
Mario Gabelli | M | 81 |
Winston Churchill Foundation
| - |
Sheila E. Widnall | M | 85 |
Massachusetts Institute of Technology
| 26 jaar |
Robert Segura | M | - | 3 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Donald Morel | M | 67 | 13 jaar | |
Patrick Zenner | M | 77 | 20 jaar | |
David Vurgait | M | 59 |
University of Pennsylvania
| 1 jaar |
Michael Zhang | M | - |
Massachusetts Institute of Technology
| 11 jaar |
Ioannis Kymissis | M | - |
Massachusetts Institute of Technology
| 9 jaar |
Benjamin van Roy | M | - |
Massachusetts Institute of Technology
| 9 jaar |
Gregory Z. Rush | M | - |
University of Pennsylvania
| 4 jaar |
Jennifer S. Moros | F | 54 |
Massachusetts Institute of Technology
University of Pennsylvania
| 7 jaar |
Paul Greenberg | M | - |
Massachusetts Institute of Technology
| 4 jaar |
Jonathan Paul Loflin | M | - |
Massachusetts Institute of Technology
| 5 jaar |
Richard J. Nelson | M | - |
Massachusetts Institute of Technology
| 5 jaar |
Tom Rikert | M | - |
Massachusetts Institute of Technology
| 5 jaar |
Sung-Hwan Shin | M | 61 |
Massachusetts Institute of Technology
| 7 jaar |
Morten Aleksandr Engel | M | - |
Massachusetts Institute of Technology
| 5 jaar |
Rob Burn | M | - |
Massachusetts Institute of Technology
| 5 jaar |
Muhammad Mohsin Al-Saggaf | M | 56 |
Massachusetts Institute of Technology
| 5 jaar |
Eric R. Cosman | M | - |
Massachusetts Institute of Technology
| 5 jaar |
Chris Turner | M | - |
Massachusetts Institute of Technology
| 6 jaar |
Vishal Kapur | M | - |
Massachusetts Institute of Technology
| 5 jaar |
Alan Chhabra | M | - |
Massachusetts Institute of Technology
| 5 jaar |
Errol Arkilic | M | - |
Massachusetts Institute of Technology
| 6 jaar |
Michael Minnich | M | 52 |
Massachusetts Institute of Technology
| 4 jaar |
David Quiram | M | 49 |
Massachusetts Institute of Technology
| 5 jaar |
Sami Shalabi | M | - |
Massachusetts Institute of Technology
| 5 jaar |
Ming-Hokng Maa | M | 48 |
Massachusetts Institute of Technology
| 5 jaar |
Tian Hang Hu | M | 46 |
Massachusetts Institute of Technology
| 5 jaar |
Kenneth Lau | M | 46 |
Massachusetts Institute of Technology
| 4 jaar |
Katie Hall | M | - |
Massachusetts Institute of Technology
| 9 jaar |
Andra Bolotin | F | 61 |
Massachusetts Institute of Technology
| 2 jaar |
Eve Phillips | F | - |
Massachusetts Institute of Technology
| 5 jaar |
George Lloyd Miller | M | 69 | - | |
Yong Li | M | 55 |
University of Pennsylvania
| 4 jaar |
Paritosh Somani | M | - |
Massachusetts Institute of Technology
| 4 jaar |
Lisa Granick | F | - |
University of Pennsylvania
| 2 jaar |
Matthias B. Jaffé | M | 50 |
Massachusetts Institute of Technology
| 3 jaar |
Robert Poor | M | - |
Massachusetts Institute of Technology
| 6 jaar |
Adnan Lawai | M | - |
Massachusetts Institute of Technology
| 7 jaar |
Paula Johnson | M | 64 | 16 jaar | |
Evren Ünver | M | - |
Massachusetts Institute of Technology
| 5 jaar |
Peter Rice | M | - |
Massachusetts Institute of Technology
| 6 jaar |
Henry Chung | M | - |
Massachusetts Institute of Technology
| 5 jaar |
Kareem Akhtar | M | - |
Massachusetts Institute of Technology
| 5 jaar |
Joan Midthun Larrea | F | 58 |
University of Pennsylvania
| 4 jaar |
Eric Liu | M | 47 | 5 jaar | |
Mohsin Ansari | M | - |
Massachusetts Institute of Technology
| 2 jaar |
Brian Chen | M | - |
Massachusetts Institute of Technology
| 5 jaar |
Shane M. Farritor | M | - |
Massachusetts Institute of Technology
| 5 jaar |
Edmundo Manuel Muniz | M | 68 |
Certara USA, Inc.
Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ. | 6 jaar |
Yong Gang Ren | M | 59 |
Massachusetts Institute of Technology
| 5 jaar |
Maria Staton | F | 54 |
Massachusetts Institute of Technology
| 2 jaar |
Shiv Vikram Khemka | M | 61 |
University of Pennsylvania
| 2 jaar |
William Federici | M | 64 | 15 jaar | |
Shalini Agarwal | F | - |
Massachusetts Institute of Technology
| 5 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 75 | 75.00% |
Zwitserland | 23 | 23.00% |
Verenigd Koninkrijk | 4 | 4.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- William Feehery
- Persoonlijk netwerk